Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Samsung Bioepis discusses its biosimilars business (Shutterstock)

More from Interviews

More from Business